RU2016110874A3 - - Google Patents

Download PDF

Info

Publication number
RU2016110874A3
RU2016110874A3 RU2016110874A RU2016110874A RU2016110874A3 RU 2016110874 A3 RU2016110874 A3 RU 2016110874A3 RU 2016110874 A RU2016110874 A RU 2016110874A RU 2016110874 A RU2016110874 A RU 2016110874A RU 2016110874 A3 RU2016110874 A3 RU 2016110874A3
Authority
RU
Russia
Application number
RU2016110874A
Other languages
Russian (ru)
Other versions
RU2016110874A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2016110874A publication Critical patent/RU2016110874A/ru
Publication of RU2016110874A3 publication Critical patent/RU2016110874A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2016110874A 2013-08-28 2014-08-28 Комбинация ингибитора alk и ингибитора cdk для лечения клеточных пролиферативных заболеваний RU2016110874A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361871275P 2013-08-28 2013-08-28
US61/871,275 2013-08-28
PCT/US2014/053244 WO2015031666A1 (en) 2013-08-28 2014-08-28 Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases

Publications (2)

Publication Number Publication Date
RU2016110874A RU2016110874A (ru) 2017-10-04
RU2016110874A3 true RU2016110874A3 (OSRAM) 2018-06-27

Family

ID=51541330

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016110874A RU2016110874A (ru) 2013-08-28 2014-08-28 Комбинация ингибитора alk и ингибитора cdk для лечения клеточных пролиферативных заболеваний

Country Status (12)

Country Link
US (2) US20160361314A1 (OSRAM)
EP (1) EP3038652B1 (OSRAM)
JP (1) JP6479812B2 (OSRAM)
KR (1) KR20160047521A (OSRAM)
CN (1) CN106029099A (OSRAM)
AU (3) AU2014312261A1 (OSRAM)
BR (1) BR112016004358A8 (OSRAM)
CA (1) CA2922684A1 (OSRAM)
ES (1) ES2674361T3 (OSRAM)
MX (1) MX2016002580A (OSRAM)
RU (1) RU2016110874A (OSRAM)
WO (1) WO2015031666A1 (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101772134B1 (ko) 2015-04-14 2017-08-29 한국화학연구원 N2-(2-메톡시페닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
WO2016167511A2 (ko) * 2015-04-14 2016-10-20 한국화학연구원 N2-(2-메톡시페닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
US11208630B2 (en) * 2015-12-24 2021-12-28 University Of Florida Research Foundation, Incorporated AAV production using suspension adapted cells
US11395821B2 (en) 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects
AU2019205821C1 (en) 2018-01-08 2025-02-13 Pharmacosmos Holding A/S G1T38 superior dosage regimes
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
EP3947368B1 (en) * 2019-04-04 2025-09-03 Dana-Farber Cancer Institute, Inc. Bifunctional compounds comprising a cdk2/5 ligand, a linker and a e3 ubiquitin ligase binding degron for the treatment of cancer
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
US20230019999A1 (en) 2019-11-18 2023-01-19 Chugai Seiyaku Kabushiki Kaisha Combination drug
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US20230117684A1 (en) * 2020-03-05 2023-04-20 Pfizer Inc. Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor
US20230381176A1 (en) * 2020-09-25 2023-11-30 Ascentage Pharma (Suzhou) Co., Ltd. A pharmaceutical composition and use thereof for treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2091918T3 (pl) * 2006-12-08 2015-02-27 Novartis Ag Związki i kompozycje jako inhibitory kinazy białkowej
CN101616895A (zh) * 2006-12-08 2009-12-30 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
US8685980B2 (en) * 2008-08-22 2014-04-01 Novartis Ag Pyrrolopyrimidine compounds and their uses
WO2010132725A2 (en) * 2009-05-13 2010-11-18 The University Of North Carolina At Chapel Hill Cyclin dependent kinase inhibitors and methods of use
EP2558092B1 (en) * 2010-04-13 2018-06-27 Novartis AG Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase 6 (cdk4/6) inhibitor and an mtor inhibitor for treating cancer
DK2670401T3 (en) * 2011-02-02 2015-09-07 Novartis Ag Methods for using the ALK-inhibitors

Also Published As

Publication number Publication date
US20160361314A1 (en) 2016-12-15
KR20160047521A (ko) 2016-05-02
EP3038652A1 (en) 2016-07-06
JP2016529285A (ja) 2016-09-23
AU2014312261A1 (en) 2016-03-10
CA2922684A1 (en) 2015-03-05
RU2016110874A (ru) 2017-10-04
MX2016002580A (es) 2016-10-26
JP6479812B2 (ja) 2019-03-06
AU2017219093A1 (en) 2017-09-14
BR112016004358A8 (pt) 2020-02-11
ES2674361T3 (es) 2018-06-29
CN106029099A (zh) 2016-10-12
WO2015031666A1 (en) 2015-03-05
US20180318305A1 (en) 2018-11-08
AU2018236813A1 (en) 2018-10-18
EP3038652B1 (en) 2018-03-21

Similar Documents

Publication Publication Date Title
BR112014017733A2 (OSRAM)
BR112014018502A2 (OSRAM)
BR112014018480A2 (OSRAM)
BR112016000471A2 (OSRAM)
BR112014018516A2 (OSRAM)
BR112014017855A2 (OSRAM)
BR112014017765A2 (OSRAM)
BR112014017669A2 (OSRAM)
BR112014021878A2 (OSRAM)
BR112016005906A2 (OSRAM)
BR112014018468A2 (OSRAM)
BR112014017901A2 (OSRAM)
BR112014019204A2 (OSRAM)
BR112014018207A2 (OSRAM)
BR112015015948A2 (OSRAM)
BR112014017722A2 (OSRAM)
BR112016011101A2 (OSRAM)
RU2016110874A3 (OSRAM)
BR112016003540A2 (OSRAM)
BR112014018578A2 (OSRAM)
BR112014018483A2 (OSRAM)
BR112014017794A2 (OSRAM)
BR112016013016A2 (OSRAM)
BR112015015312A2 (OSRAM)
BR112014024039A2 (OSRAM)

Legal Events

Date Code Title Description
FA94 Acknowledgement of application withdrawn (non-payment of fees)

Effective date: 20200415